Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs

BACKGROUND: Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated with biologic drugs. METHODS: Information on...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossa, Fabrizio, Carparelli, Sonia, Latiano, Anna, Palmieri, Orazio, Tavano, Francesca, Panza, Anna, Pastore, Maria, Marseglia, Antonio, D'Altilia, Mario, Latiano, Tiziana, Corritore, Giuseppe, Martino, Giuseppina, Nardella, Marianna, Guerra, Maria, Terracciano, Fulvia, Sacco, Michele, Perri, Francesco, Andriulli, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2021
Materias:
Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834247/
https://www.ncbi.nlm.nih.gov/pubmed/33423942
http://dx.doi.org/10.1016/j.dld.2020.12.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834247/
https://www.ncbi.nlm.nih.gov/pubmed/33423942
http://dx.doi.org/10.1016/j.dld.2020.12.120

Ejemplares similares